Vital Signs in Bleeding and Thrombosis During ECMO

Vital Signs
Study Description
Bleeding and thrombosis represent major adverse events during extracorporeal membrane oxygenation (ECMO). Complications resulting from these events can lead to death or need for long term rehabilitation support. Despite the increasing use of extracorporeal support and new technology which makes it simpler and potentially safer to apply, little scientific information regarding the predictors of bleeding or thrombosis exists.

This project sought to describe the incidence of bleeding and thrombosis in ECMO patients at Collaborative Pediatric Critical Care Research Network (CPCCRN) sites and to describe current anticoagulation monitoring practices. Additionally, it sought evidence of association between bleeding and thrombotic complications, laboratory coagulation measurements, patient characteristics, ECMO circuitry, and adherence to center-specific ECMO management protocols. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period. Data was collected on 514 subjects receiving ECMO at CPCCRN sites over a 21-month period.

生命体征（Vital Signs）
研究描述
出血与血栓形成是体外膜肺氧合（extracorporeal membrane oxygenation, ECMO）治疗期间的主要不良事件。此类事件引发的并发症可导致患者死亡，或需长期康复支持。尽管体外生命支持技术的应用日益广泛，且相关新技术使操作更简便、应用潜在更安全，但目前关于出血或血栓形成预测因素的科学研究数据仍较为匮乏。

本研究旨在明确儿科重症监护协作研究网络（Collaborative Pediatric Critical Care Research Network, CPCCRN）各中心收治的ECMO患者中出血与血栓形成的发生率，并梳理当前的抗凝监测实践现状。此外，本研究还旨在探究出血与血栓并发症、实验室凝血指标检测结果、患者特征、ECMO管路系统以及是否遵循各中心专属ECMO管理规程之间的关联。研究在21个月的周期内，共收集了CPCCRN各中心514名接受ECMO治疗患者的相关数据。